Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05929313
Other study ID # SFT-2022-001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 27, 2023
Est. completion date May 2024

Study information

Verified date May 2024
Source OrbusNeich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the acute safety and device procedural success of the Scoreflex TRIO Scoring PTCA catheters versus Scoreflex NC Scoring PTCA catheters in subjects with stenotic coronary arteries during percutaneous coronary intervention.


Description:

This is a prospective, multi-center, open-label, non-inferiority, randomized controlled trial which plans to enroll 210 subjects. All subjects enrolled will be randomly assigned to the test group (n=105) and the control group (n=105). Subjects in the test group and the control group will receive Scoreflex TRIO Scoring PTCA catheters and Scoreflex NC Scoring PTCA catheters respectively.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 210
Est. completion date May 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age = 18 and= 80. 2. Volunteer to participate in this trial and provide the written informed consent. 3. Subjects must have a single or double vessel coronary artery disease (CAD) and clinical evidence of ischemic heart disease, such as CAD, stable / unstable angina or silent ischemia, need percutaneous coronary intervention. Angiographic Inclusion Criteria 4. Subject must have de novo or restenotic lesion(s) in native coronary arteries, including in-stent restenosis suitable for percutaneous coronary intervention. 5. A maximum of two lesions that needed to be treated and they are located in two coronary arteries, including at least one target lesion, in up to two coronary arteries. 6. Target lesion must have a reference vessel diameter (RVD) between 1.75 and 4.0 mm by visual estimation. 7. Target lesion(s) must have a diameter stenosis of =70% by visual estimation. 8. The non-target lesion must be located in different coronary artery from the Target lesion. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success as visually assessed by the physician. Exclusion Criteria: 1. STEMI or NSTEMI within 7 days of study screening. 2. A serum creatinine level > 2.0 mg/dl within 7 days prior to index procedure. 3. Cerebrovascular accident (CVA) within the past 6 months. 4. Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months. 5. Left ventricular ejection fraction (LVEF) <30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary) 6. Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, 7. Subject is known to be allergic to the ingredients of the test product and the sensitivity to contrast media. 8. Subject with known pregnancy or is nursing. Women of child-bearing potential should have a documented negative pregnancy test within 7 days before index procedure. 9. Planned or actual target lesion treatment with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure. 10. Subjects who are participating in clinical research of other drugs and devices. 11. Other conditions assessed by the investigator as inappropriate to participate in this trial. Angiographic Exclusion Criteria 12. Target lesion longer than 30 mm by visual estimation. 13. Extreme angulation (90ยบ or greater) proximal to or within the target lesion. 14. Target lesion located within an arterial or saphenous vein graft or graft anastomosis 15. Previous percutaneous intervention of lesions in a target vessel (including side branches) conducted within 9 months before the study procedure and located within 10 mm from the current target lesion. 16. Target lesion demonstrating severe dissection prior to planned deployment of the investigational device. 17. Unprotected left main coronary artery disease. 18. Coronary artery spasm of the target vessel in the absence of a significant stenosis. 19. Target lesion with angiographic presence of probable or definite thrombus. 20. Target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch >2.0 mm in diameter. 21. Non-target lesion to be treated during the index procedure meets any of the following criteria: - Located within a bypass graft (venous or arterial) - Left main location - Chronic total occlusion - Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent) - Treatment not deemed a clinical angiographic success

Study Design


Intervention

Device:
OrbusNeich Scoreflex TRIO
To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters
OrbusNeich Scoreflex NC
To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters

Locations

Country Name City State
China Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou Zhejiang
China The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang
China Tong Ren Hospital Shanghai Jiao Tong University School of Medicine Shanghai
China Zhongshan Hospital Fudan University Shanghai

Sponsors (2)

Lead Sponsor Collaborator
OrbusNeich CCRC Medtech (Shanghai) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of device Procedural Success Device procedural success consisting of the following:
Successful delivery, inflation, deflation, and withdrawal of the device
No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in Thrombolysis In Myocardial Infarction (TIMI) flow from baseline as related to the devices
Residual stenosis of target lesion <50% after balloon angioplasty, Final TIMI flow grade of 3 at the conclusion of the percutaneous coronary intervention (PCI) procedure
Peri-procedural (at Day 0)
Secondary Improvement in Minimum Lumen Diameter (MLD) following use of Scoreflex NC catheter (measured by QCA). Improvement in MLD is defined as MLD post use of Scoreflex as greater than MLD from baseline. Peri-procedural (at Day 0)
Secondary In-hospital Major Adverse Cardiac Events (MACE) In-hospital Major Adverse Cardiac Events (MACE), a composite of: Cardiac death, Myocardial Infarction (MI), Target Lesion Revascularization (TLR), clinically driven. Endpoints will be measured through hospital discharge (expected to be within 24 hours)
Secondary Device-oriented target lesion failure (TLF) The device-oriented target lesion failure (TLF) is defined as a composite of cardiac death, target vessel myocardial infarction (MI), and ischemia-driven target lesion revascularization (i-TLR) 30 days
Secondary Patient-oriented composite endpoint The patient-oriented composite endpoint includes all-cause death, all MIs, or any revascularization. 30 days
See also
  Status Clinical Trial Phase
Completed NCT00069654 - Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease Phase 2
Completed NCT02919124 - Epicardial Echocardiography of Coronary Anastomoses Using the Echoclip Device N/A
Recruiting NCT02639962 - Characteristics of Culprit Lesion and Changes in Plaque Composition. A Dual Energy Cardiac CT Study N/A
Completed NCT02494557 - Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients N/A
Recruiting NCT01466452 - Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery Phase 2
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT00371891 - Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Phase 4
Completed NCT00368953 - YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus Phase 4
Completed NCT00319449 - Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED) Phase 4
Completed NCT00091754 - Atherosclerosis, Plaque and CVD in Communities
Completed NCT00069797 - Epidemiology of Coronary Heart Disease in Men Aged 40 and Over N/A
Completed NCT00024596 - Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) N/A
Completed NCT00037245 - Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA N/A
Completed NCT00006407 - Sex Steroid Hormones and Risk of CHD in Women N/A
Withdrawn NCT00006497 - Long-Term Effects of Subclinical CAD on Cardiac Function
Completed NCT00006502 - Myocardial Perfusion, Risk Factors, and Coronary Calcium N/A
Completed NCT00006309 - Pooling of Cohort Studies on Diet & Coronary Disease N/A
Completed NCT00005269 - Family Blood Pressure Program - GENOA
Completed NCT00000508 - Stanford Coronary Risk Intervention Project (SCRIP) Phase 3
Completed NCT00005147 - Epidemiology of Atherosclerosis N/A